Patents by Inventor Lior Izhar

Lior Izhar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132881
    Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Applicant: EmendoBio, Inc.
    Inventors: Lior Izhar, David Baram, Joseph Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel
  • Publication number: 20240131121
    Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.
    Type: Application
    Filed: April 5, 2023
    Publication date: April 25, 2024
    Applicant: EmendoBio Inc.
    Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
  • Publication number: 20240132884
    Abstract: The present invention relates to compositions and methods for increasing the rate of site specific insertion of a donor DNA sequence to the genome. More specifically, the method introduces a donor DNA template containing at least one transcription factor binding site to a cell in order to favor specific insertion of a donor template sequence at a target site by homology directed repair (HDR).
    Type: Application
    Filed: September 27, 2023
    Publication date: April 25, 2024
    Applicant: EmendoBio Inc.
    Inventors: David Baram, Lior Izhar, Rafi Emmanuel
  • Patent number: 11946077
    Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: April 2, 2024
    Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar, Nurit Meron
  • Publication number: 20240042025
    Abstract: RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-1538 and compositions, methods, and uses thereof.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 8, 2024
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, Rafi Emmanuel
  • Publication number: 20240002840
    Abstract: A composition comprising a non-naturally occurring RNA molecule, the RNA molecule comprising an RNA scaffold portion, the RNA scaffold portion having the structure: crRNA repeat sequence portion-Linker portion-tracrRNA portion; wherein the RNA scaffold portion forms a complex with and targets an OMNI-50 CRISPR nuclease to a DNA target site having complementarity to a guide sequence portion of the RNA molecule.
    Type: Application
    Filed: November 3, 2021
    Publication date: January 4, 2024
    Applicants: EmendoBio Inc.
    Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar
  • Publication number: 20230383273
    Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 90% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.
    Type: Application
    Filed: October 20, 2021
    Publication date: November 30, 2023
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar, Nurit Meron
  • Patent number: 11827879
    Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: November 28, 2023
    Assignee: EmendoBio, Inc.
    Inventors: Lior Izhar, David Baram, Joseph Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel
  • Patent number: 11795453
    Abstract: The present invention relates to compositions and methods for increasing the rate of site specific insertion of a donor DNA sequence to the genome. More specifically, the method introduces a donor DNA template containing at least one transcription factor binding site to a cell in order to favor specific insertion of a donor template sequence at a target site by homology directed repair (HDR).
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: October 24, 2023
    Assignee: EMENDOBIO, INC.
    Inventors: David Baram, Lior Izhar, Rafi Emmanuel
  • Publication number: 20230303989
    Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.
    Type: Application
    Filed: February 7, 2022
    Publication date: September 28, 2023
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, Nadav Marbach Bar, Liat Rockah, Nurit Meron, Ophir Adiv Tal, Ariel Gispan, Idit Buch, Nir Hecht
  • Publication number: 20230175020
    Abstract: RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-6601 and compositions, methods, and uses thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 8, 2023
    Applicant: EmendoBio Inc.
    Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
  • Publication number: 20230173105
    Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof
    Type: Application
    Filed: November 28, 2018
    Publication date: June 8, 2023
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, David Baram, Joe Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel
  • Publication number: 20230173107
    Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.
    Type: Application
    Filed: November 28, 2018
    Publication date: June 8, 2023
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, David Baram, Joe Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel
  • Publication number: 20230174974
    Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.
    Type: Application
    Filed: November 28, 2018
    Publication date: June 8, 2023
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, David Baram, Joe Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel
  • Publication number: 20230173106
    Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.
    Type: Application
    Filed: November 28, 2018
    Publication date: June 8, 2023
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, David Baram, Joe Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel
  • Patent number: 11666641
    Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: June 6, 2023
    Assignee: EMENDOBIO INC.
    Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
  • Publication number: 20230122086
    Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.
    Type: Application
    Filed: June 4, 2021
    Publication date: April 20, 2023
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, Liat Rockah, Nadav Marbach Bar, Nurit Meron
  • Publication number: 20220387515
    Abstract: Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozygous at one or more polymorphic sites selected from the group consisting of: rs10424470, rs4807932, rs10414837, rs376107533, rs3761010, rs351108, rs3826946, rs10413889, rs3761007, rs10409474, rs3761005, rs351107, rs3761001, rs740021, rs781452480, rs371057361, rs570466264, rs1041904080, rs7250194, rs17216649, rs199720952, rs6510983, rs17223066, rs7255385, rs9749274, rs111361200, rs112639467, rs141213775, rs28591229, rs10469327, rs3834645, rs1683564, rs71335276, and rs8107095, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 21-30 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a dou
    Type: Application
    Filed: November 5, 2020
    Publication date: December 8, 2022
    Applicant: EmendoBio Inc.
    Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Liat Rockah, Nadav Marbach Bar, Michal Golan Mashiach, Joseph Georgeson
  • Publication number: 20220307057
    Abstract: RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-44348 and compositions, methods, and uses thereof.
    Type: Application
    Filed: April 14, 2020
    Publication date: September 29, 2022
    Applicant: EmendoBio Inc.
    Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
  • Publication number: 20220298495
    Abstract: The present invention provides a novel gene editing composition comprising at least one fusion protein, which comprises a retrotransposon-encoded protein portion linked to a CRISPR nuclease portion, and an RNA template molecule comprising an insert template sequence.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 22, 2022
    Applicant: EmendoBio Inc.
    Inventors: Lior Izhar, Noam Diamant, Yuliya Zilberman